Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Lowering blood pressure after stroke or with diabetes poses challenges, in research and practice

High blood pressure is known as the silent killer. Researchers are finding new ways to fight back.

Lowering blood pressure after stroke or with diabetes poses challenges, in research and practice

High blood pressure is often dubbed the "silent killer" due to its often asymptomatic nature, but the risks multiply for individuals with diabetes or a history of stroke. Three studies presented at the American Heart Association's scientific sessions have explored the challenges of lowering blood pressure in these high-risk groups.

The first study investigated the use of a common diuretic in stroke patients, while the second explored the possibility of intensifying treatment to reach lower-than-standard blood pressure targets post-stroke. Lastly, the third study examined the feasibility of lowering blood pressure further in individuals with type 2 diabetes.

These findings highlight the need for a multidisciplinary approach to managing blood pressure in these vulnerable populations, as standard treatment protocols may not always be sufficient.

Brief written by urgent.news from STAT News's own syndicated text. Machine-written — may contain errors; check the original before relying on it.

Read the original at statnews.com →

More in Health & Medicine

FDA承認レナカパビル年40ドル——構造生物学が支える「分子レベルの理解」をVRで身体化する、NexoPeekのアーキテクチャと現場

FDA承認レナカパビル年40ドル——構造生物学が支える「分子レベルの理解」をVRで身体化する、NexoPeekのアーキテクチャと現場 米国FDAが安価なジェネリックHIV予防注射薬レナカパビルを承認し、インド企業が低・中所得国向けに年間40ドルで提供するというニュースは、構造生物学と計算創薬の成果が実社会で命を救う好例です。レナカパビルはHIV‑1キャプシドタンパク質の隙間に結合し、ウイルス粒子の成熟と感染の両段階を阻害します。この機構は、クライオ電子顕微鏡構造解析と分子動力学シミュレーションによって原子レベルで解明されてきました。…

More from Saturday 7 November →